Sugi Predict

Sugi Predict / Compounds / SCHEMBL38111

SCHEMBL38111

SCHEMBL38111

CC(C)(C)OC(=O)C[C@@H](N)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GRIK1 P39086 8/20 0.47
▸ SLC7A5 Q01650 2/20 0.45
▸ GRIK2 Q13002 4/20 0.44
▸ GRM1 Q13255 1/20 0.42
▸ GRM2 Q14416 1/20 0.42
▸ GRIA4 P48058 3/20 0.41
▸ GRIK3 Q13003 3/20 0.41
▸ GRIK5 Q16478 3/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ SLC1A1 P43005 4/20 0.41
▸ SLC1A3 P43003 4/20 0.41
▸ SLC1A2 P43004 4/20 0.41
▸ GRIA2 P42262 2/20 0.40
▸ GRIA1 P42261 1/20 0.40
▸ HDAC3 O15379 1/20 0.40
▸ HDAC1 Q13547 1/20 0.40
▸ HDAC2 Q92769 1/20 0.40
▸ HDAC8 Q9BY41 1/20 0.40
▸ HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2024581 1.00 GRIK1 (0.47) GRIK1SLC7A5GRIK2GRM1GRM2
SCHEMBL38112 1.00 GRIK1 (0.47) GRIK1SLC7A5GRIK2GRM1GRM2
SCHEMBL28097905 0.98 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
Hydrochloric Acid SCHEMBL6361420 0.98 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
Methane SCHEMBL15302692 0.98 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
SCHEMBL28097904 0.98 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
Methane SCHEMBL15302681 0.98 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
Water SCHEMBL27830506 0.98 GRIK1 (0.46) GRIK1SLC7A5GRIK2GRM1GRM2
SCHEMBL8149690 0.87 SLC7A5 (0.47) GRIK1SLC7A5GRIK2GRIA4GRIK3
SCHEMBL3600281 0.87 SLC7A5 (0.47) GRIK1SLC7A5GRIK2GRIA4GRIK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF AMGEN INC. (US) 2026-05-14 — — US disclosed
EP-4734980-A2 TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
EP-4734979-A2 TMEM175 AGONISTS, COMPOSITIONS, AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-05-06 — — EP disclosed
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS AZKARRA THERAPEUTICS, INC. (US) 2026-04-23 — — US disclosed
US-12606572-B2 Substituted heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2026-04-21 — — US disclosed
EP-4724445-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF Kumquat Biosciences Inc. (US) 2026-04-15 — — EP disclosed
EP-4687883-A2 MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE Caraway Therapeutics, Inc. (US) 2026-02-11 — — EP disclosed
US-20260028357-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC (US) 2026-01-29 — — US disclosed
US-20260007787-A1 RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS TRUSTEES OF TUFTS COLLEGE 2026-01-08 — — US disclosed
WO-2025264954-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-12-26 — — WO disclosed
EP-0081877-B1 LH-RH ANTAGONISTS COY, David Howard (US) 1986-04-30 — — EP disclosed
US-4534897-A Piperazinone, piperazine, 1,4-diazepin-2-one and 1,4-diazepine intermediate compounds THE UPJOHN COMPANY (US) 1985-08-13 — — US disclosed
EP-0136720-A2 Enkephalin analogs G.D. Searle & Co. (US) 1985-04-10 — — EP disclosed
US-4495178-A Enkephalin analogs G. D. SEARLE & CO. (US) 1985-01-22 — — US disclosed
EP-0041286-B1 LH-RH ANTAGONISTS Schally, Andrew Victor (US) 1984-08-15 — — EP disclosed
US-4431635-A PEPTIDE ANALOGS OF LUTEINIZING HORMONE RELEASING HORMONE; GLANDULAR DISORDERS; ANTICARCINOGENIC AGENTS COY DAVID HOWARD 1984-02-14 — — US disclosed
EP-0081877-A1 LH-RH antagonists COY, David Howard (US) 1983-06-22 — — EP disclosed
US-4317815-A PEPTIDE ANALOGS OF LUTENIZING HORMONE RELEASING HORMONE ADMINISTRATORS OF THE TULANE UNIVERSITY EDUCATIONAL FUND, THE, A CORPORATE ENTITY OF TULANE UNIVERSITY A CORP. OF LA. 1982-03-02 — — US disclosed
EP-0041286-A1 LH-RH antagonists Schally, Andrew Victor (US) 1981-12-09 — — EP disclosed
US-4251438-A ANALGESICS, PSYCHOTHERAPEUTIC AGENTS THE UPJOHN COMPANY (US) 1981-02-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260007787-A1 RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS FIBP, FRS2, FGFR1 GRIK1 4461/4885SLC7A5 471/4885GRIK2 4730/4885
US-12606572-B2 Substituted heterocycles and uses thereof KRAS, HRAS, MYC GRIK1 3585/4885SLC7A5 1804/4885GRIK2 3151/4885
US-20260132143-A1 HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF KRAS, NRAS, HRAS GRIK1 4650/4885SLC7A5 2698/4885GRIK2 4775/4885
US-20260109686-A1 PYRIDAZIN-3(2H)-ONE AND PYRIDIN-2(1H)-ONE PARP INHIBITOR COMPOUNDS PARP2, PARP1, PARP11 GRIK1 3117/4885SLC7A5 3877/4885GRIK2 3136/4885
US-20260028357-A1 SUBSTITUTED HETEROCYCLES AND USES THEREOF KRAS, HRAS, MYC GRIK1 3585/4885SLC7A5 1804/4885GRIK2 3151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.